Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Abivax has reported 3-year interim data from Study 108, a phase 2a/2b open-label extension trial of obefazimod (ABX464) in patients with moderately to severely active ulcerative colitis (UC).

 Moderately to severely active ulcerative colitis 

As described in a May 22, 2026, company announcement, the intent-to-treat (ITT) analysis showed sustained clinical remission following dose de-escalation from 50 mg to 25 mg once daily, with no new safety signals identified in patients treated for up to 7 years.

Study 108 provides the longest-running efficacy and safety dataset available for obefazimod, a first-in-class oral miR-124 enhancer. The agent previously demonstrated statistically significant clinical remission in a pair of global phase 3 induction trials, ABTECT-1 and ABTECT-2, in July 2025, generating growing interest in its potential as an oral alternative for patients with inadequate response to conventional or advanced therapies, including JAK inhibitors.²

Study 108 enrolled patients who had completed either the 4-year phase 2a or 2-year phase 2b open-label maintenance trials, during which they received 50 mg once-daily obefazimod. To be eligible for dose de-escalation, participants were required to have a Mayo Endoscopic Subscore of 0 or 1.

A total of 130 patients de-escalated to 25 mg once daily for up to 5 additional years. As of the January 5, 2026, data cutoff, 80% (104/130) of patients had completed the full 144-week evaluation.¹

At study baseline, 89% (116/130) of patients were in clinical remission. At weeks 48, 96, and 144 of treatment on the reduced 25 mg dose, clinical remission rates were 73% (95/130), 69% (90/130), and 68% (88/130), respectively, per ITT analysis with non-responder imputation. The remission definition incorporated endoscopic subscore. According to Abivax, similar trends were observed across other efficacy analyses.¹

The safety profile of obefazimod remained consistent with prior clinical experience across up to 7 years of cumulative exposure in Study 108 patients, according to Abivax.¹ No new safety signals were identified. The tolerability data extend the long-term safety characterization of the agent beyond what was available from the induction trials and earlier maintenance studies.

In a statement, Abivax's Chief Medical Officer Fabio Cataldi, MD, said the data "supports the potential of obefazimod as a durable treatment option for people living with ulcerative colitis," citing both the durability of remission and the favorable tolerability profile over the observation period.¹

The ABTECT phase 3 maintenance trial (ABX464-107) remains ongoing. Among the 1275 patients randomized across the ABTECT-1 and ABTECT-2 induction trials, 678 who achieved clinical response enrolled in Part 1 of the maintenance trial, which evaluates 44-week outcomes. Abivax has updated the expected topline readout to late Q2 2026, with a planned New Drug Application submission to the FDA in Q4 2026 contingent on positive maintenance data.¹ The company also intends to submit a Marketing Authorization Application to the European Medicines Agency in the same timeframe.

The ENHANCE-CD trial evaluating obefazimod in Crohn's disease is also underway, with a 12-week induction data readout anticipated in Q4 2026.¹

Abivax. Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis. May 22, 2026. Accessed May 28, 2026. 

https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports

Brooks A. Obefazimod Meets Primary Endpoint in Phase 3 ABECT Program for Ulcerative Colitis. HCPLive. July 23, 2025. Accessed May 28, 2026. 

https://www.hcplive.com/view/obefazimod-meets-primary-endpoint-phase-3-abect-program-ulcerative-colitis

Articles

Three-year interim results from the long-term Study 108 extension in moderate-to-severe ulcerative colitis show durable remission after obefazimod dose de-escalation from 50 mg to 25 mg once daily. Among 130 eligible patients (baseline remission 89%), intent-to-treat remission with non-responder imputation was 73% at week 48, 69% at week 96, and 68% at week 144, incorporating endoscopic criteria. Safety remained consistent with prior experience, with no new signals across up to seven years’ exposure. Phase 3 maintenance topline data are expected late Q2 2026, supporting FDA filing in Q4 2026.

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial

The Future of Wilson Disease Care: Expert Centers, Advocacy, and Clinical Hope

In the final episode, 'The Future of Wilson Disease Care: Expert Centers, Advocacy, and Clinical Hope,' the panelists explore the evolving landscape of long-term care coordination and the resources available to improve patient outcomes. Dr. Peter Hedera and Dr. Rima Fawaz emphasize the value of the Center of Excellence (COE) model, which functions as a "one-stop clinic" where hepatology and neurology are integrated to reduce the travel and appointment burden on families. They clarify that these centers should act as partners in care, providing consultative guidance to local primary care providers and gastroenterologists rather than replacing them.

A significant portion of the discussion focuses on the critical role of patient advocacy, particularly the Wilson Disease Association. The panel highlights how these organizations provide essential resources, connecting patients with peers who can offer real-world encouragement and technical advice on managing the disease. This support network, combined with the use of specialty pharmacies to track prescription fills, creates a multi-layered safety net that helps prevent patients from falling through the cracks of the healthcare system.

The experts conclude the series with a message of profound hope. While acknowledging persistent unmet needs in diagnostic monitoring and adherence, they point to a "bright future" driven by next-generation chelators and the long-term promise of gene editing. They leave clinicians and caregivers with the encouraging reminder that with early diagnosis, strict adherence, and modern multidisciplinary support, patients with Wilson disease can lead full, professional, and socially fulfilling lives—pushing the disease "to the back burner" for decades to come.

Thank you for watching this Peer Exchange series on Wilson disease. Please subscribe to our newsletter for information on upcoming video series.

Videos

Clinicians share practical ways to boost lifelong Wilson disease treatment adherence—education, monitoring, and team-based transition support.

Video Series

In this episode, “Navigating Biologic Therapy Options in IBD,” the panelists explore the evolving treatment journey for patients with inflammatory bowel disease (IBD), including experiences with biologic therapies and the path toward remission. 

Navigating Biologic Therapy Options in IBD

In this episode, “Navigating Biologic Therapy Options in IBD,” the panelists explore the evolving treatment journey for patients with inflammatory bowel disease (IBD), including experiences with biologic therapies and the path toward remission. The patient panelist reflects on the importance of communication with the care team, monitoring symptoms, and navigating treatment adjustments over time. Expert faculty discuss the rationale for initiating advanced therapies, including anti-tumor necrosis factor (TNF) agents, Janus kinase (JAK) inhibitors, and IL-23 inhibitors, while highlighting the importance of individualized treatment selection based on disease control, tolerability, and patient experience.

Throughout the discussion, the panel reviews the challenges associated with treatment switching and adverse events, including the patient’s experience with side effects while receiving a JAK inhibitor before transitioning to guselkumab, an IL-23 inhibitor. The patient panelist describes significant improvements after starting guselkumab, including resolution of urgency and fecal incontinence, improved dietary confidence, and meaningful changes in daily functioning and quality of life. Expert faculty also discuss the goals of modern IBD management, emphasizing the importance of achieving clinical remission, symptom control, and helping patients return to a more normal quality of life through advanced therapies. The conversation highlights how biologic therapies continue to reshape expectations for long-term disease management and remission in patients with IBD.

The next episode in this series, “Individualizing Biologic Therapy in IBD,” features the panelists discussing how disease severity, disease characteristics, and patient-specific factors influence biologic treatment selection in IBD. The panel also highlights the evolving role of IL-23 inhibitors, including guselkumab, and reviews considerations related to safety, administration, and early treatment intervention.

Welcome back to another HCP Live Cure Connections series. In this episode “Diagnosis and Early Treatment in IBD”, the panel explores the early patient journey in inflammatory bowel disease (IBD), including the onset of symptoms, the path to diagnosis, and the transition to specialty gastroenterology care. 

Diagnosis and Early Treatment in IBD

Welcome back to another HCP Live Cure Connections series. In this episode “Diagnosis and Early Treatment in IBD”, the panel explores the early patient journey in inflammatory bowel disease (IBD), including the onset of symptoms, the path to diagnosis, and the transition to specialty gastroenterology care. Expert faculty and the patient panelist discuss the common gastrointestinal symptoms that often prompt referral to a gastroenterologist, including abdominal pain, diarrhea, fecal incontinence, weight loss, and changes in appetite and quality of life.

The panel also reviews the diagnostic workup for IBD, including laboratory testing, imaging, stool studies, and endoscopic evaluation used to confirm Crohn’s disease or ulcerative colitis. In addition, the discussion highlights the evolving treatment landscape in IBD, including conventional therapies and advanced treatment options such as anti-tumor necrosis factor (TNF) agents, IL-23 inhibitors, S1P modulators, and JAK inhibitors. Throughout the segment, the patient panelist shares personal experiences navigating symptoms and treatment decisions, while expert faculty provide clinical context around referral patterns, treatment selection, and the importance of individualized care in managing IBD.

In the next episode, “Navigating Biologic Therapy Options in IBD,” panelists will continue their discussion on inflammatory bowel disease and highlight the patient experience with biologic therapy, including treatment transitions, symptom improvement, and the impact of remission on daily life and long-term quality of life.

The Multidisciplinary Approach to Patient Counseling and Care Transitions in Wilson Disease

In 'The Multidisciplinary Approach to Patient Counseling and Care Transitions in Wilson Disease,' our panel delves into the human elements of lifelong disease management. Dr. Peter Hedera emphasizes that clinicians can "never rest on their laurels," even with well-controlled patients, as adherence is a never-ending battle influenced by life stressors and "treatment burnout." He advocates for a tailored approach that uses objective laboratory evidence—such as shifting copper levels—to non-confrontationally re-engage patients who may be skipping doses.

Dr. Rima Fawaz highlights the high-risk period of transitioning from adolescent to adult care. She shares the Yale model’s success in creating a seamless transition through the Wilson Disease Registry, where patients often encounter the same core team across life stages. The discussion underscores that pediatric adherence is frequently driven by parents, but as patients enter young adulthood, the focus must shift to direct patient education regarding the specific mechanisms of their medication, such as why zinc must be taken away from food to remain effective.

The panel also explores the "team effort" required to maintain compliance, involving social workers, nutritionists, and medication access specialists who navigate insurance and prior authorizations. Dr. Hedera adds that health psychology and even visual aids—such as showing patients videos of their own prior symptoms—can be powerful tools for reinforcing the necessity of therapy without relying solely on fear. The experts conclude that a proactive, multidisciplinary system that tracks follow-up appointments and lab work is the most effective way to ensure long-term clinical success.

Our next episode, 'The Future of Wilson Disease Care: Expert Centers, Advocacy, and Clinical Hope,' further explores Wilson disease, highlighting the essential role of multidisciplinary collaboration and patient advocacy organizations. The experts discuss the clinical "one-stop-shop" model, the importance of referring to centers of excellence, and the optimistic future of treatment as research advances toward potentially curative genetic therapies.

Explore why Wilson’s disease patients stop lifelong therapy and how simpler, better-tolerated dosing improves adherence, preventing relapse and severe liver outcomes.

Henry Lim, MD, is the senior vice president of academic programs at Henry Ford Health. He previously served as chair of the department of dermatology.

This segment of the latest Skin of Color Savvy podcast highlighted persistent disparities in skin cancer prevention, awareness, and diagnosis.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Why is the 'Sunscreen Gap' Significant in Dermatology?

Sarath Raju, MD, from Johns Hopkins University School of Medicine.

At ATS 2026, Sarath Raju, MD, discussed retrospective data linking SGLT2 inhibitor use to reduced 30-day readmissions in patients hospitalized for AE-COPD and diabetes.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

SGLT2 Inhibitors Linked to Lower Readmission Risk After AE-COPD Hospitalization

Ferdinand shares his advice on high blood pressure management, drawing on his perspective as co-author of the ACC/AHA 2025 hypertension guidelines.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Paths Forward in Hypertension Awareness and Control, With Keith Ferdinand, MD

Christopher G. Bunick, MD, PhD, is an associate professor of dermatology at Yale University School of Medicine.

Podcasts

Explore OX40/OX40L inhibition in atopic dermatitis: phase 3 amlitelimab efficacy, safety signals, and what upstream immune control could mean.

ABCs in Dermatology

Welcome to ABC’s in Dermatology, HCPLive’s newest dermatology podcast, hosted by a pair of the field’s leading minds in Lindsay Ackerman, MD, and Chris Bunick, MD, PhD.

Created by the same team behind The Medical Sisterhood and Skin of Color Savvy, ABCs in Dermatology is a monthly podcast designed to deliver candid conversations, clinical insight, and forward-looking perspectives from the voices shaping dermatology today.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

ABCs in Dermatology: Understanding OX40L in Atopic Dermatitis

Krunal Patel, MD, of Temple University Hospital.

At ATS 2026, Krunal Patel, MD, discussed early real-world data suggesting sotatercept may improve hemodynamics, RV remodeling, and functional outcomes in group 3 CLD-PH.

Sotatercept Shows Promise in Group 3 Chronic Lung Disease Pulmonary Hypertension

The approval indicates linaclotide for pediatric patients ≥ 2 years of age with functional constipation, expanding its previous use in patients ≥ 6 years of age.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

FDA News

FDA Approves Linaclotide (Linzess) for Functional Constipation in Patients 2 Years And Older

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

These topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with moderate-to-severe atopic dermatitis.

APEX: Positive 16-Week Data Released on Zumilokibart for Atopic Dermatitis

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

FDA De Novo classification clears Cardiosense PCWP Analysis Software to estimate filling pressures in selected adults with HFrEF.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

FDA Grants De Novo Status to Cardiosense PCWP Software for HFrEF

The Liver Disease Panel represents the first comprehensive library of certified healthcare algorithms to support chronic liver disease management.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Roche Launches Liver Disease Panel, An Algorithm-Based Tool for Identifying and Managing CLD

Brittany Duchene, MD, from University of Vermont Medical Center.

Brittany Duchene, MD, found that depressive symptoms were associated with twice the odds of poorly controlled asthma.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Latest News

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial

The Future of Wilson Disease Care: Expert Centers, Advocacy, and Clinical Hope

Navigating Biologic Therapy Options in IBD

Diagnosis and Early Treatment in IBD

The Multidisciplinary Approach to Patient Counseling and Care Transitions in Wilson Disease